Xuezhu Z. Xu

157, 5th West Road
Xi'an, 710004, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Nutritional and immunologic scoring systems to predict complications and outcomes after anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma.

Nutritional and immunologic scoring systems to predict complications and outcomes after anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma.

Journal: Cytotherapy

Published: November 13, 2025

Plerixafor Plus G-CSF Versus Etoposide Combined With Cyclophosphamide and G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Single Center Observational Propensity Score-Matched Cohort Study.

Plerixafor Plus G-CSF Versus Etoposide Combined With Cyclophosphamide and G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Single Center Observational Propensity Score-Matched Cohort Study.

Journal: Journal of clinical apheresis

Published: October 13, 2025

Comparison of Thrombopoietin Receptor Agonists Plus Recombinant Human Thrombopoietin versus Recombinant Human Thrombopoietin Alone for Hematopoietic Reconstruction in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Comparison of Thrombopoietin Receptor Agonists Plus Recombinant Human Thrombopoietin versus Recombinant Human Thrombopoietin Alone for Hematopoietic Reconstruction in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: October 14, 2024

The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCMA-CAR-T cell therapy: A retrospective study based on LEGEND-2.

The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCMA-CAR-T cell therapy: A retrospective study based on LEGEND-2.

Journal: HemaSphere

Published: July 03, 2024

Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia.

Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia.

Journal: Therapeutic advances in hematology

Published: May 20, 2024

KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway.

KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway.

Journal: Journal of cancer research and clinical oncology

Published: January 10, 2024

Risk score constructed with neutrophil extracellular traps-related genes predicts prognosis and immune microenvironment in multiple myeloma.

Risk score constructed with neutrophil extracellular traps-related genes predicts prognosis and immune microenvironment in multiple myeloma.

Journal: Frontiers in oncology

Published: January 04, 2024

Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2

Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: December 04, 2023

Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2.

Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2.

Journal: British journal of haematology

Published: November 02, 2023

BATF promotes extramedullary infiltration through TGF-β1/Smad/MMPs axis in acute myeloid leukemia.

BATF promotes extramedullary infiltration through TGF-β1/Smad/MMPs axis in acute myeloid leukemia.

Journal: Molecular carcinogenesis

Published: October 13, 2023

Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.

Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.

Journal: Hematology (Amsterdam, Netherlands)

Published: October 05, 2023

N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1/p21cip1/waf1/CDK2-Cyclin E1 axis-mediated cell cycle transition.

N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1/p21cip1/waf1/CDK2-Cyclin E1 axis-mediated cell cycle transition.

Journal: Oncogene

Published: November 29, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026